Zanubrutinib Plus GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in Previously Untreated Follicular Lymphoma

Exclusion Criteria

• •1. Central nervous system involvement secondary to lymphoma.
• •2. Known severe allergic reactions to humanized or murine monoclonal antibodies, or known contraindications to any drug in the regimen.
• •3. History of other active malignant diseases within 2 years prior to study entry, but eligibility for inclusion: a) adequately treated carcinoma in situ of the cervix; b) local basal cell carcinoma or squamous cell carcinoma of skin; c) Pre-existing malignant disease that is under control and has undergone local radical treatment (surgical or other forms).
• •4. History of Human Immunodeficiency Virus (HIV) infection and/or other acquired Immunodeficiency syndrome. During screening period, patients with hepatitis B virus (HBV) surface antigen or hepatitis C virus (HCV) antibody positive must further test HBV DNA (no more than 2000 iu/ml) and HCV RNA (not exceed the method detection limit). Those ruling out active HBV or HCV infection are permitted to participate in the study. Carriers of the HBV, those with stable HBV after treatment or cured of HCV are also allowed to be enrolled.
• •5. Any active infections, including but not limited to bacterial, fungal or viral infections, that require systemic anti-infective treatment within 14 days prior to initiation treatment.
• •6. Major surgery was performed within 28 days prior to initiation treatment.
• •7. Combined with severe or uncontrolled disease, including but not limited to congestive heart failure, uncontrolled hypertension, unstable angina, active peptic ulcer, severe hemorrhagic diseases (such as hemophilia, von willebrand disease) or spontaneous bleeding.
• •8. History of stroke or intracranial hemorrhage within 6 months prior to initiation treatment.
• •9. Continuous treatment with strong and moderate CYP3A inhibitors or CYP3A inducers is required.
• •10. History of severe neurological or psychiatric disorders, including but not limited to dementia or epilepsy.
• •11. Conditions related to drug abuse or medical, psychological and social issues that may interfere with study participation or outcome evaluation.
• •Investigator Discretion: Any patient deemed unsuitable for enrollment by the investigator.
• •12. Patients deemed unsuitable for the study by investigators.